B Braun reports positive data from SeQuent Please trial

B Braun has highlighted data from a new clinical study showcasing the safety and efficacy benefits of its paclitaxel-eluting balloon SeQuent Please.

The ISAR-Desire 3 trial evaluated the effectiveness of the device for the treatment of in-stent restenosis among coronary artery disease patients, compared to an uncoated balloon or a drug-eluting stent.

It was found that B Braun's product was able to deliver a strong performance in terms of minimising binary restenosis, while also helping to prevent death and myocardial infarction.

Dr Sergej Kammerzell, product management director for vascular systems at B Braun, said: "With the current clinical evidence, SeQuent Please can be considered as a reasonable alternative to drug-eluting stents for selected patients with coronary artery disease."

SeQuent Please has recently received recommendations from the European Society of Cardiology, German Society of Cardiology and the UK's National Institute for Health and Clinical Excellence.

Meanwhile, findings from the Swedish SCAAR registry highlighted last month showed that the device performed better in studies than a number of other drug-eluting balloons.